Ceva Live is an educational seminar series for our customers. Ceva virtual events provide the latest information and education covering the most innovative advancements throughout poultry. Our platform hosts industry leading CEVA scientists presenting on a range of poultry topics, including lessons learned from COVID-19 and mRNA vaccines. Sessions conclude with a live Q&A, where guests can join the conversation. All Ceva Live speaker bios can be found below. Read on to learn more about our most recent virtual events New Year, New Perspectives: The Future of Respiratory Health and Solutions to Complex Disease Challenges.
Covid-19 is driving technical changes for vaccine developments in both human and animal health. These technologies are bringing safer and more efficacious vaccines into production. New recombinants and Lipid Nanoparticles (LNPs) delivering mRNA are entering the market at a faster pace. These and other novel vaccines such as viral like particles (VLPs), DNA plasmid vaccines, self-replicating RNA, DNA, and RNA deliver enhanced safety and efficacy that allows our customers to significantly scale production.
In 2020 BRON MASS was launched, a classic Mass vaccine. BRON MASS in the perfect companion for IBRON to provide effective, relevant and board protection. BRON MASS is used by 34% of the US broiler population and is the go-to vaccine for protection against GA08, GA13, DMV1693 and Ark. BRON MAASS is the most relevant cross-protection vaccine of our times.
Vector vaccines, largely rFP-LT are the cornerstone of ILT control in Latin America. Over the last 20 years there has been almost no ILT outbreaks throughout most of Latin America. Ceva is the behind this industry changing development with Vectormune FP-LT.
Applying field applications of Stochastic (SIR) models for controlling disease transmission carries over lessons learned from the spread of COVID-19 to poultry. This statistical/probability model helps reduce infections and mortalities leading to fewer and smaller outbreaks. Ceva recently provided industry first evidence of a powerful vector rHVT-ND vaccine applying SIR models that induced less virus shedding, providing significant reduction of virus transmission.
